Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014)

Akebia Therapeutics' (AKBA) quarterly Capital Leases came in at $6369.0 in Q2 2014, down 13.51% on a QoQ basis from $7364.0 in Q1 2014.

Akebia Therapeutics (AKBA) Capital Leases (2013 - 2014) Analysis & Trends

Akebia Therapeutics (AKBA) has 2 years of Capital Leases data on file, last reported at $6369.0 in Q2 2014.

On a quarterly basis, Capital Leases changed N/A year-over-year to $6369.0 in Q2 2014; TTM through Jun 2014 was $6369.0, a N/A change from a year earlier, with the FY2013 full-year figure at $8004.0, changed N/A from the prior year.
Capital Leases for Q2 2014 stood at $6369.0, down from $7364.0 in the prior quarter.
Over the last five years, Capital Leases for AKBA reached as high as $8004.0 in Q4 2013 and fell as low as $6369.0 in Q2 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Akebia Therapeutics	325.80 Mn	163.20 Mn	41.25 Mn

Download Data